Barclays analyst Benjamin Theurer maintained a Hold rating on Corteva (CTVA – Research Report) today and set a price target of $58.00. The company’s shares closed last Friday at $57.48.
According to TipRanks, Theurer is a 4-star analyst with an average return of 5.7% and a 55.87% success rate. Theurer covers the Consumer Defensive sector, focusing on stocks such as Coca Cola Femsa SAB De CV, Beyond Meat, and Pilgrim’s Pride.
Currently, the analyst consensus on Corteva is a Moderate Buy with an average price target of $63.73, representing a 10.87% upside. In a report released on May 5, Goldman Sachs also maintained a Hold rating on the stock with a $61.00 price target.
Based on Corteva’s latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $6.05 billion and a net profit of $714 million. In comparison, last year the company earned a revenue of $6.25 billion and had a net profit of $965 million
Based on the recent corporate insider activity of 68 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of CTVA in relation to earlier this year. Earlier this month, BRIAN TITUS, the VP, Controller and Principal Accounting Officer of CTVA sold 12,134.00 shares for a total of $687,317.90.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Corteva (CTVA) Company Description:
Corteva, Inc. is an agricultural chemical and seed company. It develops and supplies advanced germplasm and traits that helps in maximizing yield for farms. It also supplies products that enhances enhance crop health and protectagainst weeds, insects and other pests, and diseases.
Read More on CTVA:
